Stoke Therapeutics Execs to Present at Canaccord Growth Conference
Event summary
- Stoke Therapeutics CEO Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026.
- The presentation will be webcast live and archived on Stoke’s investor relations website.
- Stoke is developing zorevunersen, a first-in-class potential disease-modifying treatment for Dravet syndrome, currently in Phase 3 trials.
- Zorevunersen has received multiple regulatory designations, including FDA Breakthrough Therapy Designation and orphan drug status from both the FDA and EMA.
The big picture
Stoke Therapeutics is leveraging RNA medicine to address Dravet syndrome, a rare epileptic encephalopathy. The company’s proprietary TANGO approach aims to restore protein expression, positioning it in the competitive landscape of gene therapy and antisense oligonucleotides. With Biogen as a strategic partner for global commercialization, Stoke’s success hinges on regulatory milestones and clinical trial outcomes.
What we're watching
- Clinical Progress
- The pace at which zorevunersen advances through Phase 3 trials will determine its commercial viability.
- Regulatory Dynamics
- Whether the Breakthrough Therapy Designation accelerates FDA approval timelines for zorevunersen.
- Partnership Strategy
- How Biogen’s role in commercializing zorevunersen outside North America impacts Stoke’s revenue potential.
Related topics